PFE vs TSLA: Which Is the Better Buy?
Side-by-side comparison of Pfizer Inc. and Tesla, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
VS
Tesla, Inc. · Consumer Cyclical
$372.11
+45.0% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
TSLA has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
PFE |
TSLA |
| Current Price |
$27.64 |
$372.11 |
| Fair Value Estimate |
$30.94 |
$539.56 |
| Upside to Fair Value |
+12.0%
|
+45.0%
|
| Market Cap |
$157.5B |
$1,469.7B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
17.4x
|
121.7x
|
| Price / Sales |
2.5x
|
14.2x
|
| Price / FCF |
14.3x
|
209.1x
|
| Revenue Growth YoY |
+2.6%
|
+25.5%
|
| Gross Margin |
71.3%
|
18.9%
|
| Operating Margin |
25.1%
|
4.2%
|
| Return on Equity |
4.9%
|
4.6%
|
| Dividend Yield |
6.22% |
0% |
| FCF Yield |
6.97%
|
0.48%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Tesla, Inc. designs, manufactures and sells electric vehicles and energy generation and storage systems, operating through Automotive and Energy Generation and Storage segments with 134,785 full-time employees and a market capitalization of $1,469.67 billion at a share price of $372.11. The business quality is mixed: revenue grew 25.5% year over year in the most recent quarter, but earnings fell …
Accumulation Zones
| Metric |
PFE |
TSLA |
| Zone Low |
$23.21 |
$404.67 |
| Zone High |
$26.30 |
$458.63 |
| In Buy Zone? |
No
|
Yes
|